Insula Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-07-2024
- Paid Up Capital ₹ 0.10 M
as on 16-07-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -97.07%
(FY 2023)
- Profit -134.10%
(FY 2023)
- Ebitda -116.03%
(FY 2023)
- Net Worth -5.74%
(FY 2023)
- Total Assets -39.23%
(FY 2023)
About Insula Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shaik Janimiya, Shaik Thahera, Javeed Shaik, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304TG2017PTC117548
- Company No.
117548
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Insula Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shaik Janimiya  | Managing Director | 05-Jun-2017 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shaik Junaid | Director | 18-Jan-2021 | Current |
| Shaik Thahera | Whole-Time Director | 05-Jun-2017 | Current |
| Javeed Shaik | Whole-Time Director | 05-Jun-2017 | Current |
Financial Performance of Insula Pharmaceuticals.
Insula Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 97.07% decrease. The company also saw a substantial fall in profitability, with a 134.1% decrease in profit. The company's net worth dipped by a decrease of 5.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Insula Pharmaceuticals?
In 2023, Insula Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Crescent Formulations Private LimitedActive 14 years 1 monthShaik Janimiya, Shaik Thahera and 2 more are mutual person
Crescent Therapeutics Private LimitedActive 4 years 11 monthsShaik Janimiya, Shaik Thahera and 2 more are mutual person
- Gmp Formulations Private LimitedActive 6 years 10 months
Shaik Janimiya, Shaik Thahera and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Insula Pharmaceuticals?
Unlock and access historical data on people associated with Insula Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Insula Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Insula Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
